Windlas Biotech

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0H5O01029
  • NSEID: WINDLAS
  • BSEID: 543329
INR
961.45
-19.35 (-1.97%)
BSENSE

Nov 20

BSE+NSE Vol: 35.0 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Syncom Formul.
Sakar Healthcare
Venus Remedies
NGL Fine Chem
Windlas Biotech
Beta Drugs Ltd
Indoco Remedies
Hester Bios
Sai Parenteral's
Panacea Biotec
Dishman Carbogen
Why is Windlas Biotech Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
Poor long term growth as Operating profit has grown by an annual rate 12.74% of over the last 5 years
3
Flat results in Mar 26
  • ROCE(HY) Lowest at 14.90%
  • CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 1.81 cr
4
Stock is technically in a Mildly Bullish range
  • The technical trend has improved from Sideways on 05-Nov-26 and has generated 4.13% returns since then
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band and OBV
5
With ROE of 11.4, it has a Expensive valuation with a 3.4 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 19.33%, its profits have fallen by -0.5% ; the PEG ratio of the company is 18.1
6
Falling Participation by Institutional Investors
  • Institutional investors have decreased their stake by -2.57% over the previous quarter and collectively hold 9.32% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Windlas Biotech should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Windlas Biotech for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Windlas Biotech
19.33%
0.48
39.89%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
16.92%
EBIT Growth (5y)
12.74%
EBIT to Interest (avg)
32.88
Debt to EBITDA (avg)
0.21
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
1.37
Tax Ratio
23.59%
Dividend Payout Ratio
20.04%
Pledged Shares
0
Institutional Holding
9.32%
ROCE (avg)
21.49%
ROE (avg)
11.33%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
30
Industry P/E
40
Price to Book Value
3.41
EV to EBIT
23.60
EV to EBITDA
16.67
EV to Capital Employed
5.05
EV to Sales
1.93
PEG Ratio
18.08
Dividend Yield
0.66%
ROCE (Latest)
21.40%
ROE (Latest)
11.44%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET SALES(Q)

Highest at Rs 238.50 cr

-3What is not working for the Company
ROCE(HY)

Lowest at 14.90%

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 1.81 cr

Loading Valuation Snapshot...
Here's what is working for Windlas Biotech
Net Sales - Quarterly
Highest at Rs 238.50 cr and Grown
each quarter in the last five quarters
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Here's what is not working for Windlas Biotech
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 1.81 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents